Transparency Market Research Report Added “Menopausal Hot Flashes Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 – 2023” to its database.
Albany, NY -- (SBWIRE) -- 02/21/2017 -- In the moderately fragmented global market for menopausal hot flashes, the top eight companies accounted for a collective share of more than 50% in 2014, states TMR in a recent report. The top two vendors, Pfizer, Inc. and Novartis AG held a dominant share of nearly 30% of this, commanding a strong hold on the overall development prospects of the market.
Pfizer, the topmost vendor in the market, benefits from its strong foothold in North America, which happens to be the leading consumer of menopausal hot flashes treatment products across the globe. In the next few years, increased awareness regarding the potential effects of hormone-based treatments in triggering cancers and cardiovascular diseases in women will bring about major transformation in the overall dynamics of the global market.
For Any Queries Get Solutions With A PDF Sample: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2856
Several leading therapies, such as Merck's Colpotrophine (promestriene) and Pfizer's Premarin, have lost patents and many products are also losing exclusivity. This will have a significant effect on the overall market dynamics in the next few years and witness the influx of cheaper generic treatment methods. Also, to support the rising demand for alternative treatment methods, companies in the market will increasingly invest on research and development of non-hormonal treatments for menopausal hot flashes.
Rising Prevalence of Menopausal Vasomotor Symptoms Remains Key Vehicle for Market's Growth
The rising prevalence of menopausal vasomotor symptoms, especially across developed regions such as North America and Europe, is expected to be the most prominent stimulator for the global menopausal hot flashes market in the next few years. According to the North American Menopause Society, as many as 75% perimenopausal women in the U.S. experience hot flashes. Incidence rate of hot flashes in other western countries is also similar to the U.S., making these regions the prime destination for the menopausal hot flashes market.
Hormone-based therapies are presently the leading treatment modalities in the market. However, through 2023, concerns about the severe side-effects of hormone replacement therapies and their potential in triggering cardiovascular diseases and cancers will massively transform the menopausal hot flashes treatment paradigm. In effect, the market for once popular treatment modalities, including hormone pills, patches, and gels, will be taken over by alternative non-hormonal treatments. The dearth of effective alternatives capable of favoring this trend will be reflected in the moderate growth prospects of the global menopausal hot flashes market over 2015 to 2023.
Growing Awareness about Women's Health in Developing Countries Presents Newfound Growth Opportunities
Several population-based surveys have demonstrated that there has been a swooping rise in health awareness among women across developed and developing parts of the world in the past few years. This factor has aided the increased adoption of a variety of treatment methods for menopause-related symptoms, especially in developing regions such as Asia Pacific.
Active efforts for raising healthcare awareness among women across developing and underdeveloped parts of the world could aid the increased adoption of treatments for a variety of menopause-related symptoms in the next few years. These regions present ample growth opportunities for the market owing to large population base and the rising number of women aged between 35 and 65 years.
View exclusive Global strategic Business report: http://www.transparencymarketresearch.com/menopausal-hot-flashes.html
The global menopausal hot flashes market had an opportunity worth US$3.77 bn in 2014. The market is projected to rise at a moderate CAGR of 3.7% over the period between 2015 and 2023, and rise to US$5.28 bn by 2023. Despite declining popularity, treatment methods based on estrogen and progestin remain the leading treatment methods in the market owing to the absence of effective alternatives. Hormone-based treatments will also continue to play a prominent role in the overall development of the market for many years to come.
About Transparency Market Research
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company's exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR's experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.
Transparency Market Research
90 State Street,
NY - 12207
USA - Canada Toll Free 866-552-3453